Which K-Bio Companies Are Global Pharma Eyeing? Let's Invest in KOSDAQ Biotech with Knowledge! We Explain the Hard Stuff Easily | Noh Young-rae, Yeo Do-eun, Heo Jae-mu

Summary

Noh Young-rae explains anticancer treatment modalities using military analogies and profiles five KOSDAQ biotech companies: ABL Bio, IntoCell, Orum Therapeutics, ST Cube, and Bio Solution. The discussion highlights Korea's competitive position in ADC components, BBB shuttle technology, linker platforms, DAC protein degraders, BTN1A1 immuno-oncology, and cartilage regeneration. The market implication is that KOSDAQ biotech offers selective high-risk, high-potential opportunities, but clinical and partnership outcomes remain binary and volatile.

• Noh Young-rae uses military analogies to explain chemo, immuno-oncology, targeted therapy, and ADC mechanisms.
• The episode highlights Korea's competitive position in ADC components such as linkers and payloads rather than complete drug development.
• ABL Bio is presented as a BBB shuttle/double-antibody platform with global pharma interest and a next-generation GrabBody T pipeline.
• IntoCell is framed as a linker specialist seeking validation and clinical expansion, while Orum Therapeutics is a DAC/degrader-payload story with BMS and Vertex deals.
• ST Cube is an early-stage BTN1A1 immuno-oncology name targeting PD-L1 non-responders, and Bio Solution is a cartilage-regeneration play.
• The hosts frequently note that biotech investing requires deeper study because clinical and partnership outcomes are binary and volatile.
• The video ends with a market volatility caution and no explicit buy/sell recommendation.